StudentShare
Contact Us
Sign In / Sign Up for FREE
Search
Go to advanced search...
Free

Economic Analysis of Patented Drugs vs. Generic Drugs - Research Paper Example

Cite this document
Summary
Drugs frequently have several terms. When a new drug is first researched, it is provided a chemical term, which explains the molecular configuration of that drug. …
Download full paper File format: .doc, available for editing
GRAB THE BEST PAPER93.6% of users find it useful
Economic Analysis of Patented Drugs vs. Generic Drugs
Read Text Preview

Extract of sample "Economic Analysis of Patented Drugs vs. Generic Drugs"

?Introduction: Drugs frequently have several terms. When a new drug is first researched, it is provided a chemical term, which explains the molecularconfiguration of that drug. The chemical term is thus normally too difficult and awkward for common use. Thereafter, a shorthand edition of that chemical term or a codename (such as RU 486) is brought up for easy indication among scientist. When the drug is accepted by the administration agency liable for making sure that the drugs being marketed in the country are not dangerous and efficient, it is provided with a generic (official) title and a business (proprietary or brand) title. The business title is made by that company requesting sanction for a drug and recognition for it as the special feature of that particular company. As for example, phenytoin which is the common name and Dilantin is the business name for a single drug. When one drug is in rights security, the company sells it with its business name. When a drug is out of the patent protection (no longer protected by patent), the company may sell the products under whichever name they want common name or business name. Other companies which file for authorization to sell that off-patent drug have to use the similar common name but have the freedom to use their own trade name. This results in drugs to be sold in the same generic name but multiple trade names. (Aronsson et al. 2001) General drugs are remedies that are known by the chemical formulae instead of their brand, or business name. Most of the people, as for example, know the brand title Valium, however the common name of the anxiety defiant drug is diazepam. (Mehta & Mehta, 1997) In the most cases, most drugs are likewise as efficient as brand-name remedies. They too are typically lesser expensive than the brand names, frequently as a great deal as 50 % or more. What is the reason behind this? (Mehta & Mehta, 1997; Aronsson et al. 2001) Pharmaceutical industries spend a lot of time (usually a decade or more) and cash—generally more money than $300 million—to research, develop, produce, and marketing a brand new drug. Which results in, if the efforts become positive, the brand-name drug which is patented plus sold solely under a particular business name for seventeen years, which permits the industry get back more money than it invested. As a patent runs out, or there is not any patent at all, other industries can produce and market that drug with the drug’s common name or with other brand names. Other industries don’t need to invest the time and wealth to get the actual drug to the market. Therefore, they can sell the drug at a lower cost. (Mehta & Mehta, 1997; Aronsson et al., 2001) Economic analysis of patent protection versus generic drugs: The limit of the patent security in helping the mechanisms for making novel remedies not supposed to be minimized. To get a fresh prescription remedy in the market, industries of pharmaceutics must beat several obstacles including large investments for researching and development (R&D), authoritarian scrutiny very importantly scientific trustworthiness corresponding the protection and effectiveness of that fresh drug. To attain this, companies continuously search for fresh compounds having medicinal power. When a brand new, hopeful substance is found, the industry files a request for patent security while it goes through different levels of Research and Development. Current estimations of the expense of developing a fresh drug is ranged between $230 million and $500 million prior to the remedy can be marketed. (Mehta & Mehta, 1997) Getting patent security for a particular remedy, the industry has the power to set the price as per wish; without contest, no descending pressure is there upon the price from different probable drug providers. The monopoly supremacy gained from that patent protection gives inducement for drug industries to put in a big capital needed for Research and Development by permitting them in earning much more than the possible result in more contesting market. With no patent security, other industries would take the drug’s chemical configuration at an expense much low than the primary costs of Research and Development by the actual firm. Industries wanting to bring in a good turnover from getting into the market for the remedy would start manufacturing the drug so the contest would force the market to bring even more competitive result where the entire market and not any individual company determines the price. In this case, where an industry incurs huge fixed expenses through Research and Development while other industries have least fixed expense, there are some incentives to up bring new, inventive drugs. (Aronsson et al. 2001; Frank& Salkever, 1997). Not only the industries are trying to get over the set expense associated with Research and Development, but there could be large changeable costs linked with selling patented drugs. Differing from other consumer goods which can be taken directly by barter between the buyer and the seller, prescription remedies are taken by customers only after a consultation with a physician, and getting a prescription from him and authorizing the purchase. On more, the physician is not permitted legally to profit from writing prescription and the customers have to take that prescription to a pharmacist who is independent for purchasing. Previous, pharmaceutical industries concentrated their marketing actions primarily upon the physicians, pursuing them to recommend the medicine for the well being of the patients. As the doctors’ action includes the patient’s interest also this marketing policy was quite effective. (Aronsson et al. 2001; Frank& Salkever, 1997). Nevertheless, around the 1980s the FDA began permitting straight-to-customer marketing by the pharmaceutical industries. These days, the influencing process is extended to the consumers also for the increment of the marketing of a product. The motive behind straight-to-customer marketing holds the concept that getting enlightened about a product will have them requesting to the physician for it. This changed system has increased the expense of the advertisement of the product equaling to the Research and Development costs. (Aronsson et al. 2001; Frank& Salkever, 1997). In variation, patent unprotected medicines have the power of being manufactured by any company that holds the belief of earning profit from it. These companies do not possess the outlay of Research and Development involved in making a new remedy, but only confronts the expenses related to reproduction and marketing a established medication. The industries producing generic alike have a lot lesser average price and so can still generate a profit in offering a priced product to consumers. On expiration of a drug patent and generic replacements show up in the market, theories related to economics predict that there ought to be a reduction in the remedy’s price as the factors like product demand is unaltered. (Aronsson et al. 2001; Frank & Salkever, 1997). Several surveys have concluded the impacts of generic vs. brand-name costs on expiration of a drug’s patent. Few observed effort in this field clarified two usual outcomes. Firstly the situation says that patent unprotected remedies getting into the market got lesser price equivalents of the drug name. In addition, market shares of a branded remedy declines, but it is also noted by the authors that contradictory evidence exists in the empirical studies regarding whether the cost of patented drugs originally increases or falls down on introducing the generic drugs. Observations suggested that brand name prices falls on introduction of the generics. Sometimes they may rise also but in that case their market shares fall. They consider this as a consequence of segmentation with customers who are brand-loyal and willing to pay higher price for the recognized drug name while others chose the less-costly generics. Nevertheless, their outcomes highlighted the shift in market shares from brand titles to generic titles resulting in a less average cost for a remedy issue to market contests. Overall, the accessibility of generics drugs leads to lesser-priced products for customers and their utilization in the places of much-priced brand name remedies should force to lessened health care expenditure. (U.S. General Accounting Office, 1993; Frank& Salkever, 1997). Conclusion: In the review, the big prices of prescription remedies are derived by market forces and government involvement. Patented remedies gets advantage from the government authorized monopoly and manufacturers of these remedies are capable of setting prices in places of their belief where they are sure of getting profit without competitions like low-priced products. Like this, they get the chance to earning enough profits to for the set Research and Development costs and the expenses of manufacturing and marketing the remedy. Since a particular firm that will market a patented drug, will confront the total market demand curve; holding other factors invariable. In this case, an increase in demand for a product will result in an increase in the price. Industries may boost revenue as well as profit potential with aggressive marketing to probable users of that remedy and also to physicians for prescribing. And since companies are conscious that patent security is given for a stipulated time, they will possibly attempt to create market shares and overcome R&D expenses before generic remedies are obtainable for contesting. Nevertheless, without the inducements given by the primary patent security, an unconfident company will not manufacture new, pioneering products having potential to improve the standard of human health. (Aronsson et al, 2001) References: 1. Aronsson, T., Bergman, M.A., & Rudholm, N. (2001). The impact of generic drug competition on brand name market shares — evidence from micro data. Review of Industrial Organization, 19(4):425-435. 2. Mehta, S.C., & Mehta, S.S. (1997). Strategic options for brand-name prescription drugs when patents expire. Health Marketing Quarterly, 14(3): 107-114. 3. Frank, R.G., & Salkever, D.S. (1997). Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy, 6(1): 75-90. 4. U.S. General Accounting Office. (1993). Prescription drug prices: Analysis of Canada's Patented Medicine Prices Review Board. Retrieved from http://www.archive.gao.gov/d36t11/148527.pdf ( on 20th May, 2011) Read More
Cite this document
  • APA
  • MLA
  • CHICAGO
(“Economic Analysis of Patented Drugs vs. Generic Drugs Research Paper”, n.d.)
Retrieved from https://studentshare.org/family-consumer-science/1422642-economic-analysis-of-patented-drugs-vs-generic
(Economic Analysis of Patented Drugs Vs. Generic Drugs Research Paper)
https://studentshare.org/family-consumer-science/1422642-economic-analysis-of-patented-drugs-vs-generic.
“Economic Analysis of Patented Drugs Vs. Generic Drugs Research Paper”, n.d. https://studentshare.org/family-consumer-science/1422642-economic-analysis-of-patented-drugs-vs-generic.
  • Cited: 0 times

CHECK THESE SAMPLES OF Economic Analysis of Patented Drugs vs. Generic Drugs

Improvements of the marketing planning process in the pharmaceutical company

An analysis of  the market status of Actavis AD  within the Bulgarian pharmaceutical industry, along the significant economic  determinants operating in all markets, namely, supply and demand, barriers to entry and the pricing of goods, production cost and profit, aids in understanding the company's market status and in devising future strategies.... hellip; The author states that the sustained growth of Actavis is attributed to its continuously increasing portfolio, enhance ment in sales volume and value of its product(due to their better quality) , development of all-inclusive range of theurapeutic drugs, thechnological upgradation and commitment to intoduce new, safe and affordable drugs....
16 Pages (4000 words) Essay

HIV/AIDS in Sub-Saharan Africa

A rapid drop in prices, accompanied by a near-abandonment of intellectual property and the widespread availability of inexpensive generic drugs, has revealed that stumbling blocks in progress against HIV/AIDS in sub-Saharan Africa are not drug prices or patents.... The paper "HIV/AIDS in Sub-Saharan Africa" discusses how one can ethically justify and challenge the reluctance of the major transnational pharmaceutical corporations in playing an active role in the eradication of the HIV/AIDS pandemic, as well as to sustain while selling drugs to developing nations of Africa....
7 Pages (1750 words) Term Paper

Legal Strategies Pursued by Multinational Companies

According to Constance Bagley, managers of MNC should know how business risk can be minimized by understanding the law and thereby creating value to the business. The… rpose of this research is to analyze the complexity involved in MNCs business in the areas that have legal implications like insider trading laws , intellectual property issues pertaining to launch of a new product , hiring and dismissing employees , an age discrimination case Legal strategy plays a key role for multinational companies (MNC) in business decision and operation process....
9 Pages (2250 words) Essay

The Global Pharmaceutical Industry

This made possible several 'me too' drugs to realize significant profits on investment.... This produced the emergence of 'generic' drugs.... The influence of generic application is exemplified by Bristol Myers Squibb's brand Glucophage, a cure for diabetes, which produced US sales of $2.... By the end of the 1970s generic entrants and more stringent controls on clinical trials had led to substantial increases in R&D spending....
11 Pages (2750 words) Coursework

Pharmaceutical indusrry

One of the ways of achieving this is by marketing these drugs.... Unlike most consumer drugs that can be purchased from the seller to the buyer directly, these drugs have to be prescriptions from the doctor or physician.... Without these prescriptions, the drugs cannot be legally sold.... However, as time went by, the FDA (Food and drugs Administration), began letting the pharmaceuticals to do direct consumer exchanges (Acemoglu, p 1)....
4 Pages (1000 words) Essay

The Complexity Behind the Implementation of a Single Market Policy in the EU

Eventually, the rules of the competition that were applied in the context of the pharmaceutical industry will be thoroughly examined, including analysis of reasons why competition rules may be inapplicable to the pharmaceutical industry.... Sterling drugs Inc.... nbsp; Back in 1974, Centrafarm purchased a large volume of pharmaceutical products from European countries at a relatively low price and sold the drugs in the Netherlands at a higher price....
19 Pages (4750 words) Case Study

What Are the Industrys Dominant Economic Features

focuses on the fact that the pharmacy industry comprises of establishments known as pharmacies and drug stores engaged in retailing prescription and non-prescription drugs and medicines.... Per capita expenditure on drugs was $1069 in 2006, which is almost double of that found in the rest of the world.... In addition, the increasing life expectancy of the American population and the new Medicare-endorsed the prescription program, an introduction of new drugs and the rate of inflation, all demonstrate towards increased demand for pharmaceutical products (Drug Week, 2006)....
8 Pages (2000 words) Research Paper

Strategic Options for Brand-Name Prescription Drugs When Patents Expire

This paper "Strategic Options for Brand-Name Prescription drugs When Patents Expire" focuses on the fact that drugs frequently have several terms.... The drug is accepted by the administrative agency liable for making sure that the drugs being marketed in the country are not dangerous and efficient.... This results in drugs to be sold in the same generic name but multiple trade names.... 2001)General drugs are remedies that are known by the chemical formulae instead of their brand, or business name....
6 Pages (1500 words) Research Paper
sponsored ads
We use cookies to create the best experience for you. Keep on browsing if you are OK with that, or find out how to manage cookies.
Contact Us